68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2018-02-02 eCollection Date: 2018-02-01 DOI:10.2217/ije-2017-0005

Jasmine Shell, Xavier M Keutgen, Corina Millo, Naris Nilubol, Dhaval Patel, Samira Sadowski, Myriem Boufraqech, Lily Yang, Roxanne Merkel, Christine Atallah, Peter Herscovitch, Electron Kebebew

{"title":"68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.","authors":"Jasmine Shell, Xavier M Keutgen, Corina Millo, Naris Nilubol, Dhaval Patel, Samira Sadowski, Myriem Boufraqech, Lily Yang, Roxanne Merkel, Christine Atallah, Peter Herscovitch, Electron Kebebew","doi":"10.2217/ije-2017-0005","DOIUrl":null,"url":null,"abstract":"Aim: The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging.Methods: Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial.Results: Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT. Of the patients identified by 68-Gallium DOTATATE PET-CT, 50% (n = 1) had a treatment change and 100% showed symptom improvement. Of the biochemically negative patients (n = 11), 68-Gallium DOTATATE PET-CT identified NETs in 64% (n = 7). Change in management occurred in 71% patients, and 57% of patients showed symptom improvement.Conclusion: 68-Gallium DOTATATE PET-CT imaging is useful in detecting NETs in symptomatic patients with negative anatomical imaging and changes the treatments in these patients.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2018-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2017-0005","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrine Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ije-2017-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 15

Abstract

Aim: The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging.

Methods: Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial.

Results: Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT. Of the patients identified by 68-Gallium DOTATATE PET-CT, 50% (n = 1) had a treatment change and 100% showed symptom improvement. Of the biochemically negative patients (n = 11), 68-Gallium DOTATATE PET-CT identified NETs in 64% (n = 7). Change in management occurred in 71% patients, and 57% of patients showed symptom improvement.

Conclusion: 68-Gallium DOTATATE PET-CT imaging is useful in detecting NETs in symptomatic patients with negative anatomical imaging and changes the treatments in these patients.

Abstract Image

查看原文本刊更多论文

68- DOTATATE镓扫描在解剖成像阴性但怀疑神经内分泌肿瘤的症状患者中的应用。

目的:本研究的目的是确定68-镓DOTATATE正电子发射断层扫描(PET)-CT扫描在具有类癌样症状和阴性解剖成像的患者中的应用。方法:回顾性分析196例具有类癌样症状且解剖成像和内窥镜检查无原发性神经内分泌肿瘤(NET)证据的患者中的22例，这些患者接受了68-镓DOTATATE PET-CT检查，作为前瞻性临床试验的一部分。结果:在生化阳性患者(n = 11)中，18% (n = 2)在68-镓- DOTATATE PET-CT上有额外的NETs证据。在68-镓- DOTATATE PET-CT鉴别的患者中，50% (n = 1)的治疗改变，100%的患者症状改善。在生化阴性的患者(n = 11)中，68-镓- DOTATATE PET-CT鉴别出了64%的NETs (n = 7)。71%的患者发生了治疗改变，57%的患者表现出症状改善。结论:68-镓- DOTATATE PET-CT显像对有症状且解剖显像阴性的NETs有检测价值，可改变治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.